Increase in Solubility of Poorly-Ionizable Pharmaceuticals by Salt Formation: A Case of Agomelatine Sulfonates
journal contributionposted on 29.08.2017, 00:00 by Eliška Skořepová, Daniel Bím, Michal Hušák, Jiří Klimeš, Argyro Chatziadi, Luděk Ridvan, Tereza Boleslavská, Josef Beránek, Pavel Šebek, Lubomír Rulíšek
The search for new solid forms of an active pharmaceutical ingredient (API) is an important step in drug development. Often, an API has a low water solubility, which then leads to low oral bioavailability. For basic or acidic APIs, the rational solution is the preparation of salts. For neutral, poorly ionizable, compounds, the cocrystallization is often the only choice. Agomelatine, a poorly soluble “nonionizable” amide acting as a melatonergic antidepressant is a typical representative of such class of compounds. Until recently, the only multicomponent forms of agomelatine were cocrystals. In this work, we report the preparation of three salts of agomelatine (hydrogensulfate, mesylate, and besylate) and their solvated forms, along with their crystallographic characterization. Interestingly, the crystal structures of the solvated and nonsolvated hydrogensulfates were determined from the same crystal via a topotactic transformation. In all of the structures, the agomelatine molecule was positively charged with the amide oxygen being protonated. The salt formation was also confirmed by solid state nuclear magnetic resonance measurements and density functional theory calculations. By sulfonate salt formation, up to ∼200-times faster dissolution of agomelatine was achieved, which proves that salts might be an attractive alternative even for the poorly ionizable compounds.
Read the peer-reviewed publication
ionizable compoundssolvated formswater solubilityAgomelatine Sulfonatescrystal structuressulfonate salt formationagomelatine moleculetheory calculationsmelatonergic antidepressantsalt formationamide oxygenmulticomponent formsacidic APIsSalt Formationnonsolvated hydrogensulfatesresonance measurementstopotactic transformationdrug developmentpreparationPoorly-Ionizable Pharmaceuticals